{"organizations": [], "uuid": "257e4edd4fc9c5acd48e4fba97acb6620369a4ea", "thread": {"social": {"gplus": {"shares": 1}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 5}, "facebook": {"likes": 121, "shares": 114, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.marketwatch.com", "main_image": "http://mw2.wsj.net/mw5/content/logos/mw_logo_social.png", "site_section": "http://www.marketwatch.com/rss/realtimeheadlines/", "section_title": "MarketWatch.com - Real-time Headlines", "url": "http://www.marketwatch.com/investing/stock/bmy", "country": "US", "domain_rank": 900, "title": "Bristol-Myers Squibb entered into a $2 bln accelerated share repurchase agreement", "performance_score": 1, "site": "marketwatch.com", "participants_count": 0, "title_full": "Bristol-Myers Squibb entered into a $2 bln accelerated share repurchase agreement", "spam_score": 0.0, "site_type": "news", "published": "2017-02-21T19:01:00.000+02:00", "replies_count": 0, "uuid": "257e4edd4fc9c5acd48e4fba97acb6620369a4ea"}, "author": "", "url": "http://www.marketwatch.com/investing/stock/bmy", "ord_in_thread": 0, "title": "Bristol-Myers Squibb entered into a $2 bln accelerated share repurchase agreement", "locations": [], "entities": {"persons": [{"name": "victor reklaitis", "sentiment": "none"}, {"name": "philip van doorn", "sentiment": "none"}, {"name": "ono pharma", "sentiment": "none"}, {"name": "emma court", "sentiment": "none"}, {"name": "nigam arora", "sentiment": "none"}, {"name": "tomi kilgore", "sentiment": "none"}], "locations": [], "organizations": [{"name": "asr", "sentiment": "negative"}, {"name": "squibb", "sentiment": "negative"}, {"name": "emma court  bristol-myers squibb", "sentiment": "none"}, {"name": "bristol-myers squibb", "sentiment": "none"}, {"name": "merck", "sentiment": "none"}, {"name": "emma court  merck", "sentiment": "none"}, {"name": "marketwatch.com", "sentiment": "none"}, {"name": "emma court", "sentiment": "none"}, {"name": "ono pharma", "sentiment": "none"}, {"name": "factset", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Bristol-Myers to receive about 80% of the ASR shares on Feb. 28 1 min ago 7:02 a.m. Feb. 21, 2017 - Tomi Kilgore \nBristol-Myers Squibb entered into a $2 bln accelerated share repurchase agreement 2 min ago 7:01 a.m. Feb. 21, 2017 - Tomi Kilgore 2:48 p.m. Jan. 31, 2017 - Philip van Doorn 6:21 a.m. Jan. 31, 2017 - Barrons.com 12:00 a.m. Jan. 28, 2017 - Barrons.com 11:48 a.m. Jan. 27, 2017 - Nigam Arora 1:11 p.m. Jan. 26, 2017 - MarketWatch.com 7:20 a.m. Jan. 26, 2017 - MarketWatch.com 7:19 a.m. Jan. 26, 2017 - Emma Court \nBristol-Myers' stock falls 0.6% premarket after Q4 results 7:03 a.m. Jan. 26, 2017 - Tomi Kilgore \nBristol-Myers cut 2017 adj. EPS outlook to $2.70-$2.90 from $2.85-$3.05 7:02 a.m. Jan. 26, 2017 - Tomi Kilgore \nBristol-Myers Q4 revenue $5.24 bln vs. $4.29 bln; FactSet consensus $5.12 bln 7:01 a.m. Jan. 26, 2017 - Tomi Kilgore \nBristol-Myers Q4 adj. EPS 63 cents; FactSet consensus 67 cents 7:01 a.m. Jan. 26, 2017 - Tomi Kilgore \nBristol-Myers Squibb Q4 EPS 53 cents vs. per-share loss 12 cents a year ago 7:00 a.m. Jan. 26, 2017 - Tomi Kilgore 9:38 a.m. Jan. 25, 2017 - Nigam Arora 4:21 p.m. Jan. 20, 2017 - Victor Reklaitis 4:16 p.m. Jan. 20, 2017 - Emma Court \nMerck will pay $625 million and royalties to settle with Bristol-Myers Squibb and Ono Pharma, they say 4:06 p.m. Jan. 20, 2017 - Emma Court \nBristol-Myers Squibb and Ono Pharma say they have settled all patent litigation related to Merck's Keytruda 4:05 p.m. Jan. 20, 2017 - Emma Court 11:11 a.m. Jan. 20, 2017 - Emma Court", "external_links": [], "published": "2017-02-21T19:01:00.000+02:00", "crawled": "2017-02-21T14:06:39.300+02:00", "highlightTitle": ""}